Snapshot as of end 2023
19
Pipeline
Projects
5
Innovation
Platforms
12
5
Licensing Deals
(since 2018)
The Experimental Drug Development Centre (EDDC) is Singapore’s national platform for drug discovery and development. We collaborate with public sector and industry partners to translate groundbreaking scientific discoveries into valuable biotherapeutic candidates.
About Us
17
5
9
Public and Private Collaborations
5
Licensing Deals
(since 2018)
Little Drug, Big Hope
ETC-159 is a selective small molecule inhibitor of Porcupine, a key component of the Wnt signalling pathway. Developed in collaboration with Duke-NUS, it has completed Phase 1B trials and showed promising outcomes for patients with platinum-resistant ovarian cancer.
One such patient, Iren, with her husband Kevin, share about their journey and how Iren found renewed life through the ETC-159 clinical trial. Alongside her, Veronica Diermayr from EDDC, A/Prof David Tan from NCIS, and Prof David Virshup from Duke-NUS delve into the science, collaboration, and inspiration behind this made-in-Singapore oncology drug.
ETC-159 is beginning its Investigator-Initiated Trial at NUHS focused on patients with advanced MSS/pMMR ovarian cancers.
Pipeline
EDDC aims to develop innovative therapeutics and companion diagnostics that have the potential to improve and save the lives of patients in Singapore and beyond. We want to advance the development of safe and effective therapies that address unmet medical needs.
We welcome partnerships with collaborators who share our vision, to jointly accelerate the development of our pipeline assets.
Find Out More About Drug Discovery
Playlist
Newsroom
EBC-129: Phase 1 study of our first-in-class, anti N-glycosylated CEACAM5 & 6 ADC in solid tumours
Recent News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development
First Made-in-Singapore Antibody-Drug Conjugate EBC-129 progresses to Phase 1B Dose Expansion
ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics
Partner with Us
EDDC is equipped with comprehensive capabilities for advancing the discovery and development of small molecule or antibody-based drugs, as well as companion diagnostics.
As a publicly-funded researcher, you can benefit from our extensive expertise and capabilities to advance your drug discovery project in various ways.
Consultancy
Services